[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Maryland, College Park\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":268},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,77,108,128,153,182,219,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100543071","longitudinal-investigation-of-sleep-memory-and-brain-development-across-the-nap-transition-100543071",false,"NCT06351098","Longitudinal Investigation of Sleep, Memory, and Brain Development Across the Nap Transition","HSR","Inclusion Criteria:\n\n1. 36-60 months at the time of enrollment\n2. must be a habitual napper (defined as napping 5 or more days\u002Fweek on average for the past month)\n3. must sleep independently (not bedsharing; in order to maintain consistent sleep not interrupted by others)\n\nExclusion Criteria:\n\n1. diagnosis of any sleep disorder (other than mild parasomnia which is routine at this age) past or present (Child's Sleep Habit Questionnaire)\n2. current use of psychotropic or sleep-altering medications (Developmental, Health, and Environment Questionnaire)\n3. traveling beyond 1 time zone within 1 month prior to testing (phone screening)\n4. fever or symptoms of respiratory illness at the time of testing (phone screening)\n5. physical handicap which interferes with assessments (vision, hearing impairment; phone screening)\n6. diagnosed developmental disability (Developmental, Health, and Environment Questionnaire)\n7. history of neurological injury such as history of seizures, brain tumor, or stroke (phone screening)\n8. presence of metal in the body (e.g., implant of any form) or other contraindication for MRI (e.g., claustrophobia, which is rare at this age).\n9. external influences on nap habits (e.g., inability to nap due to school or caregiver schedule or interfering activities during a typical naptime) including if the child will enroll in full-day kindergarten by the end of the study. Caregivers will also be queried for the presence of interfering activities throughout enrollment (e.g., ecological momentary assessment (or EMA), sleep diaries at each wave).",true,"ALL","36 Months","60 Months",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","To examine the relations between sleep (nap transitions, sleep physiology), memory, and brain development longitudinally, the researchers will assess n=180 children (in order to acquire n=152 usable data sets) who are 36-54 months of age and habitual nappers at enrollment. In each wave, the researchers will assess memory, memory change over a nap and equivalent waking interval, sleep physiology of the nap, and brain structure and function (using Magnetic Resonance Imagining or MRI). Additionally, overnight sleep physiology will be assessed in all participants. Waves will take place approximately every 6 months. For all children, three waves will be collected. With these data, the researchers will address the following aims:\n\n* Examine neural markers that predict the sleep transition (Aim 1);\n* Examine changes in sleep-dependent memory processing (mnemonic discrimination) over both nap and overnight sleep intervals, across the sleep transition (Aim 2);\n* Examine changes in sleep microstructure in both nap and overnight sleep across the sleep transition (Aim 3)\n* Examine interrelations among brain, memory and sleep microstructure across the sleep transition (Aim 4)",[28],"Memory",[30,31],"Sleep","Brain development","RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-04","ACTUAL",{"date":38,"type":36},"2023-11-05",{"date":40,"type":22},"2028-06",{"name":42,"class":43},"University of Maryland, College Park","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100514081","peer-recovery-to-improve-polysubstance-use-and-mobile-telemedicine-retention-100514081","NCT05973838","Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention","Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area","PRISM","Inclusion Criteria:\n\nPatient participants in the RCT must be 18 or older; receive OUD treatment as part of the telemedicine program; and exhibit polysubstance use within the past three-months (i.e., use of one or more non-prescribed substances (excluding opioids and\u002For tobacco) by urine toxicology or self-report.\n\nExclusion Criteria:\n\n* Demonstrating active, unstable or untreated psychiatric symptoms, including mania and\u002For psychosis that would interfere with study participation\n* Inability to understand the study and provide informed consent in English","18 Years",{"count":55,"type":22},160,[25],"The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led, brief, behavioral intervention to improve adherence to medication for opioid use disorder (MOUD) and reduce polysubstance use among patients with OUD and polysubstance use in underserved areas. The intervention is based on behavioral activation (BA) and is specifically designed to be implemented by a trained peer recovery specialist. In this hybrid, Type-1 effectiveness-implementation randomized controlled trial (RCT), the investigators will evaluate the effectiveness and implementation of Peer Activate vs. treatment as usual (TAU) over twelve months.",[59,60,61,62,63],"Polysubstance Addiction","Opioid Medication Assisted Treatment","Treatment Adherence","Retention in Care","Substance-Related Disorders",[63,65,66,67],"Opioid-Related Disorders","Polysubstance Use","Mental disorders","2026-04-21",{"date":70,"type":36},"2026-04-27",{"date":72,"type":36},"2023-06-15",{"date":74,"type":22},"2027-09-01",{"name":42,"class":43},4,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100619279","evaluating-modes-of-influenza-transmission-2b-baseline-sar-100619279","NCT07342556","Evaluating Modes of Influenza Transmission 2b Baseline SAR","EMIT-2b: Evaluating Modes of Influenza Transmission Through the Conduct of Controlled Human Influenza Virus Infection Transmission Trials (CHIVITTs)","EMIT-2b-1","Inclusion Criteria Recipients:\n\n1. Enrolled in the Recipient Registry (UMD IRB Protocol # 2303473, eligible age ≥18 and ≤49)\n2. Provides written informed consent, can comply with the planned study procedures, is available for an up to \\~14-day home semi-quarantine period, and can attend scheduled exposure events and scheduled follow-up visits.\n3. Participants must be able to comprehend the study requirements, as evidenced by a score of 100% on the comprehension assessment (repeated tries permitted).\n4. No significant change (for the worse) in general health history or in concomitant medication use, as compared from their responses collected during screening (Recipient Protocol).\n5. Live in a private, single occupancy bedroom and agree to take precautions to avoid contracting a respiratory infection outside of the controlled exposure events through a home semi-quarantine prescribed by investigators.\n6. Agree not to meet with other participants (Recipients or Donors) outside of the programmed exposure events during their participation in the home semi-quarantine.\n\nExclusion Criteria Recipients:\n\n1. Female of childbearing potential who has a positive urine pregnancy test within 24 hours of enrollment in a Recipient Cohort or is breastfeeding or planning to become pregnant within 2 months after enrollment.\n2. Presence of infection with influenza, SARS-CoV-2, or other respiratory pathogens detected via a multiplex nucleic acid amplification test (e.g., TaqMan Array Card assay) at entry to the transmission trial.\n\n   a. Volunteers with influenza infection may be eligible to enroll as Donors.\n3. Within the past 72 hours, presence of influenza-like illness, as defined as fever of ≥100.2°F AND cough or sore throat, in the absence of an alternative cause.\n4. Receipt of any blood products within the past 2 months.\n5. Does not agree to provide permission for secondary research use of extra samples collected and stored specimens.\n6. Habitual smoker of tobacco, marijuana, or e-cigarettes per self-report. (Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion.)\n7. Self-reported or known history of alcohol or drug abuse in the past two years and\u002For illicit drug use within the last 30 days. (Prescribed stimulants for the treatment of ADHD and cannabinoids use do not constitute exclusionary criteria)\n8. Has an ongoing symptomatic condition for which the individual has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan. (symptomatic condition means for example ongoing chronic fatigue without a diagnosis for symptom.)\n9. Presence of self-reported or medically documented significant medical or psychiatric condition(s) Significant medical or psychiatric conditions include but are not limited to:\n\n   1. Respiratory disease (e.g., chronic obstructive pulmonary disease \\[COPD\\], asthma, cystic fibrosis) requiring daily medications\\* currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years. (\\* Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.)\n   2. Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.\n   3. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).\n   4. Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible.\n   5. An autoimmune disease.\n   6. An immunodeficiency of any cause.\n   7. A blood disorder (e.g., sickle cell disease)\n   8. Endocrine disorders (e.g., diabetes)\n   9. Liver, kidney, metabolic disorders\n   10. BMI ≥40 kg\u002Fm2\n   11. Persistent post-viral syndromes with ongoing cardiovascular, respiratory, or neurologic conditions.\n   12. Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the screening or future transmission studies.\n10. Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness. Including, but not limited to, corticosteroids exceeding 10 mg\u002Fday of prednisone equivalent, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 2-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted.\n11. Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to oseltamivir, baloxavir, acetaminophen\u002Fparacetamol).\n12. History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis.\n13. Participating in any other interventional clinical trial that has a scheduled intervention 30 days prior to the start or after the end of the home semi-quarantine.\n\nInclusion Criteria Donors:\n\n1. Provides written informed consent, able to comply with the planned study procedures, available for between 1 and 5 days of multiple hour daily transmission experiments in a controlled environment research facility for the transmission trial and can attend the scheduled follow-up visits.\n2. Comprehends the study requirements, as evidenced by a score of 100% on the comprehension assessment (repeated tries permitted).\n3. Males and non-pregnant, non-breastfeeding females1 aged ≥18 and ≤59 years of age, at time of initial consent. Pregnancy and breastfeeding status to be determined by self-report.\n4. Agrees to the collection of specimens for secondary research.\n5. Evidence of onset of respiratory infection within the past 48 hours at time of entry into the Donor's initial exposure event, including one or more of the following:\n\n   1. Onset of influenza-like illness, as defined as fever (measured oral temperature of ≥100.2°F or self-reported fever in the absence of a measured temperature) AND cough or sore throat in the setting of local influenza activity.\n   2. Onset of less specific symptoms with a positive molecular test for influenza virus infection.\n   3. Laboratory-confirmed influenza infection (including rapid antigen test in the setting of known local influenza activity) with significant exposure to a laboratory confirmed influenza case (e.g., a roommate) within the last 4 days in the absence of symptoms.\n\nExclusion Criteria Donors:\n\n1. Female of childbearing potential who is breastfeeding or has positive urine pregnancy test upon enrollment.\n2. Presence of self-reported or medically documented significant medical or psychiatric condition(s) Significant medical or psychiatric conditions include but are not limited to:\n\n   1. Respiratory disease (e.g., chronic obstructive pulmonary disease \\[COPD\\], asthma, cystic fibrosis) requiring daily medications currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years. Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.\n   2. Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.\n   3. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).\n   4. Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible.\n   5. An autoimmune disease.\n   6. An immunodeficiency of any cause.\n   7. A blood disorder (e.g., sickle cell disease)\n   8. Endocrine disorders (e.g., diabetes)\n   9. Liver, kidney, metabolic disorders\n   10. BMI ≥40 kg\u002Fm2\n   11. Persistent post-viral syndromes with ongoing cardiovascular, respiratory, or neurologic conditions.\n   12. Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the transmission study over the next several days.\n   13. Meets criteria for escalation of care at the time of enrollment visit (will be referred for care).\n3. Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness Including, but not limited to, corticosteroids exceeding 10 mg\u002Fday of prednisone equivalent, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 2-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted.\n4. Ongoing symptomatic condition for which individual has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.\n\n   e.g., ongoing and debilitating fatigue without a diagnosis for the symptom.\n5. Self-reported or known history of alcohol or drug abuse within the past two years or illicit drug use within the last 30 days.\n6. Is a habitual smoker of tobacco, marijuana, or e-cigarettes per self-report. Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion.\n7. Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to acetaminophen\u002Fparacetamol).\n8. History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis.\n9. Presence of infection with SARS-CoV-2, as detected via a multiplex nucleic acid amplification test (e.g., Cepheid 4-Plex).\n10. Participating in any other interventional clinical research study that has a scheduled intervention 30 days prior to or after the transmission trial.\n11. Any condition, to include medical and psychiatric conditions, that in the opinion of the Investigator, might interfere with the safety of the participant or the study objectives.","49 Years",{"count":87,"type":22},80,[25],"This is a research study to investigate how influenza transmits from person-to-person. Participation as a healthy \"Recipient\" in this study involves:\n\n* Home semi-quarantine lasting about 14 days during which the participants must wear an N95 in class and take other precautions\n* Daily assessments and clinic visits for 14 days\n* Spending every weekday evening for about 14 days from around 6 - 10 pm, including a provided dinner, in a controlled environment. There may be additional sessions and different required participation times on weekends\n* Exposure to people infected with influenza in the controlled environment\n* Three blood draws, at the start, at the end of 14 days, and about a month after the end.\n* A follow-up clinic visits one month after the end of home semi-quarantine\n* A two-month follow-up phone call. This study may increase the participant's risk of catching influenza.\n\nIf the participants get infected during the study, the investigators may:\n\n* Provide the participants with a prescription for antiviral medication or\n* Refer the participants for medical care\n* Ask the participants to become a Donor and expose other Recipients.\n\nThe participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for an infection resulting from the study, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.\n\nIf the participants are someone who recently became infected with influenza either through their daily activities or by participating in this study as a Recipient, they are invited to participate in this research study as a Donor and interact with a group of health participants in a controlled environment. Participation in this study as a Donor involves exposing Recipients for at least one and up to five days including:\n\n* Attend exposure events in a controlled environment\n\n  * Weekday evenings from around 6-10 pm\n  * Additional day and evening events on weekends\n  * Events include a provided dinner\n* Daily assessments and clinic visits for 1 to 5 days\n* Provide exhaled breath samples for 30 to 60 minutes\n* Three blood draws, at the start and end of exposure events, and about a month after the end\n* A follow-up clinic visit one month after their last exposure event\n* A two-month follow-up phone call\n\nIf the participants experience severe symptoms related to their influenza infection, we may:\n\n* Provide the participants with a prescription for antiviral medication or\n* Refer the participants for medical care\n\nThe participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for their influenza infection, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.",[91],"Influenza (Healthy Volunteers)",[93,94,95,96,97],"influenza","airborne transmission","infection transmission","touch transmission","spray (droplet) transmission","NOT_YET_RECRUITING","2026-01-13",{"date":101,"type":36},"2026-01-15",{"date":103,"type":22},"2026-01",{"date":105,"type":22},"2026-05",{"name":42,"class":43},1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100603286","using-the-smart-underwear-device-to-determine-a-baseline-of-flatus-activity-normalized-to-fiber-intake-100603286","NCT07134543","Using the Smart Underwear Device to Determine a Baseline of Flatus Activity Normalized to Fiber Intake","Inclusion Criteria:\n\n* 18 years old or older\n* Lives in the US\n* Is not pregnant or lactating\n* Is willing to wear the Smart Underwear device as instructed in the study procedures\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Lives outside the US\n* Is pregnant or lactating\n* Is not willing to wear the Smart Underwear device as instructed in the study procedures",{"count":115,"type":22},500,"OBSERVATIONAL","The goal of this observational study is to quantify the typical frequency of flatulence in healthy adults, normalized by fiber intake, using the Smart Underwear device. The study will enroll a maximum of 500 adults across the United States who will wear the device for three consecutive days while continuing their usual daily activities.\n\nThe main questions it aims to answer are:\n\n* What is the average frequency of flatus events in a general adult population?\n* How does dietary fiber intake influence flatus frequency and microbiome activity?\n\nResearchers will collect gas sensor data from the Smart Underwear device alongside dietary information logged in a mobile app to assess the relationship between diet and microbiome activity.\n\nParticipants will:\n\n* Complete an online eligibility survey, consent form, and background questionnaire.\n* Wear the Smart Underwear device for at least 12 hours per day for three consecutive days.\n* Log all meals with photos using a custom smartphone app.\n* Complete a short post-wear survey about device comfort and usability.\n\nAll study procedures will be conducted remotely. Data will be analyzed in de-identified form to evaluate baseline flatulence patterns, normalized to fiber intake, in the general adult population.",[119],"All Health Backgrounds to Determine a Baseline of Flatus Activity","2025-12-19",{"date":122,"type":36},"2025-12-23",{"date":124,"type":36},"2025-12-01",{"date":126,"type":22},"2026-12-01",{"name":42,"class":43},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100520583","an-evaluation-of-an-online-sexual-assault-resistance-program-idea3-100520583","NCT06058455","An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)","A Randomized Controlled Trial of the Efficacy of IDEA3 - An Evidence-based Sexual Assault Resistance Intervention for Undergraduate Women Adapted for Internet Delivery","IDEA3","Inclusion Criteria:\n\n* 1st- and 2nd-year university students at one of the 4 sites\n* female-identifying students\n* students between ages of 17-24\n* able to attend one of the scheduled program groups\n* able and willing to be matched with another eligible student\n\nExclusion Criteria:\n\n\\- None","17 Years","24 Years",{"count":139,"type":22},1920,[25],"The goal of this randomized trial is to test whether the Internet-Delivered Enhanced Assess, Acknowledge, Act (IDEA3) sexual assault resistance education intervention reduces sexual violence victimization in undergraduate women.\n\nParticipants in the intervention group will be asked to attend four three-hour group sessions of a sexual assault resistance program called IDEA3 with a partner, as well as fill out a number of surveys. Participants in the control group will be asked to attend a one-hour consent workshop with a partner and fill out surveys.\n\nResearchers will compare sexual assault victimization between the groups in the one year following the intervention.",[143],"Sexual Assault","2025-10-18",{"date":146,"type":36},"2025-10-21",{"date":148,"type":36},"2023-10-02",{"date":150,"type":22},"2027-12-31",{"name":42,"class":43},6,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":16,"sex":17,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":170,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":44},"100503411","hands-and-hearts-together-100503411","NCT05834907","Hands and Hearts Together","Prevention of Attachment Insecurity, Physiological Dysregulation, and Child Behavior Problems","Inclusion Criteria:\n\n* Parents whose children (age 8 to 36 months) are enrolled or are eligible to be enrolled in Harrisburg PA and Lehigh Valley PA Early Head Start programs\n\nExclusion Criteria:\n\n* Parents who are not sufficiently fluent in the language in which COS-P intervention will be conducted (Spanish or English)","8 Months",{"count":162,"type":22},249,[25],"Growing evidence demonstrates that secure attachment in childhood predicts children's healthy social, biological, and behavioral functioning, whereas insecure attachment predicts behavior problems and physiological dysregulation; thus, efforts to foster secure attachment are crucial for promoting the healthy development of children and families. This proposal describes a randomized controlled trial (RCT) of an innovative intervention program that can be widely implemented designed to foster children's secure attachment, promote healthy physiological regulation, and reduce the risk for behavior problems: The Circle of Security ® Parenting (COS-P) intervention. To this end, investigators will conduct an RCT with 249 parent-child dyads enrolled or are eligible but not yet enrolled in two diverse Early Head Start (EHS) programs.",[166,167,168,169],"Parent-Child Relations","Development, Infant","Parenting","Development, Child",[166,167,168,169,171,172,173],"Attachment","Home Visiting","Early Intervention","2025-06-30",{"date":176,"type":36},"2025-07-03",{"date":178,"type":36},"2023-03-27",{"date":180,"type":22},"2027-06-30",{"name":42,"class":43},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":204,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":107},"100591839","khanya-ekhaya-a-home-based-intervention-100591839","NCT06985641","Khanya Ekhaya: A Home-Based Intervention","Home-Based Community Health Worker Support for Mental Health Among People Living With HIV in South Africa: A Hybrid Effectiveness Implementation Trial","Inclusion Criteria:\n\nCHWs:\n\n* at least 18 years old\n* must conduct home visits for people with HIV newly initiating or re-initiating ART at the approved clinic site\n\nPATIENTS:\n\n* at least 18 years old\n* seen by a CHW after newly initiating or re-initiating ART in the past three months\n* screen positive for depressive symptoms or harmful alcohol use\n\nExclusion Criteria:\n\nCHWs:\n\n-Unable or unwilling to complete informed consent and study procedures in English, isiXhosa, or Afrikaans\n\nPATIENTS:\n\n-Unable or unwilling to complete informed consent and study procedures in English, isiXhosa, or Afrikaans",{"count":190,"type":22},119,[25],"Mental health conditions, such as depression, anxiety, and harmful alcohol use are prevalent among people with chronic diseases, including HIV, and contribute to poor engagement in care. There is a need to address untreated mental health problems. Community health workers (CHWs) are frontline workers who play a central role in supporting vulnerable individuals to stay in care, including seeking people living with HIV who are newly initiating antiretroviral therapy (ART) or re-initiating after a period of care disengagement. CHW-delivered interventions are promising for improving engagement and retention in care. Yet, these programs rarely address mental health -a significant barrier to chronic disease care engagement and treatment. An approach that moves beyond providing care in the clinic setting is needed. Community-delivered home-based mental health care has been shown to be feasible and acceptable and shows promise for integration into broader community health care services for people with chronic conditions, such as HIV.",[194,195,196,197,198,199,200,201,202,203],"HIV","HIV Antiretroviral Therapy (ART) Adherence","Mental Health","Substance Use Disorders","Stigma","Community Health Workers","Training","Global Health","Mental Health Recovery","Substance Use Recovery",[199,205,201,203,202,194,206,207,208,209,210,197],"Health Personnel","Health Care Seeking Behavior","Treatment Adherence and Compliance","Attitude of Health Personnel","Substance Use Stigma","Mental health Stigma","2025-05-14",{"date":213,"type":36},"2025-05-22",{"date":215,"type":22},"2025-09-01",{"date":217,"type":22},"2026-06-15",{"name":42,"class":43},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":16,"sex":17,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":244,"locationsCount":44},"100439075","speech-perception-and-high-cognitive-demand-100439075","NCT04997577","Speech Perception and High Cognitive Demand","Auditory-cognitive Training Paradigm (NIH P01 Project - Speech Perception With High Cognitive Demand)","Inclusion Criteria:\n\n* Aged between 65 - 85 years\n* Normal hearing (pure tone thresholds ≤ 25 dB HL from 250 - 8000 Hz)\n* Self-reported normal or corrected-to-normal vision\n* Dominant language: American English\n* Education: a high school diploma or higher education level\n\nExclusion Criteria:\n\n* Middle-ear or inner-ear pathology\n* Non-native speaker of English\n* Inability to complete all training sessions within a pre-specified time window (e.g., due to unexpected schedule restrictions)\n* Learning disorders\n* Metal in body that induces a data artifact for MEG recording (e.g., excessive metal dental work) or that poses a safety issue in the MRI portion (e.g., pacemakers, neural implants, metal plates or joints, shrapnel, and surgical staples)\n* Claustrophobia or any condition that would be exacerbated by the scanning environment's lighting, sounds, etc. (e.g., migraines)\n* A non-removable hairstyle or hair accessory that would prevent the participant from fitting comfortably in the MEG or MRI head coil\n* Currently under a medical provider's care for a closed head injury\n* Currently taking psychoactive stimulant (e.g., amphetamines), depressant (e.g., benzodiazepines), mood stabilizing (e.g., lithium), anti-psychotic, or anti-seizure medications or drugs of abuse\n* Currently pregnant (only for MRI)","65 Years","85 Years",{"count":229,"type":22},100,[25],"With advancing age, adults experience increasing speech understanding difficulties in challenging situations. Currently, speech-in-noise difficulties are rehabilitated by providing hearing aids. For older normal-hearing adults, however, hearing devices do not provide much benefit since these adults do not have decreased hearing sensitivity. The goal of the \"Speech Perception and High Cognitive Demand\" project is to evaluate the benefit of a new auditory-cognitive training paradigm. In the present study neural (as measured by pupillometry and magnetoencephalography) and behavioral changes of speech-in-noise perception from pretest to posttest will be examined in older adults (age 65 - 85 years) assigned to one of three training groups: 1) Active Control Group: sessions of watching informational videos, 2) Auditory Training Group: sessions of auditory training listening to one of two speakers in everyday scenarios (e.g., driving directions) and needing to recall what one speaker said in the previous sentence, and 3) Auditory-cognitive training group: identical to the auditory training group, except participants will be asked to remember information from two previous sentences. Changes in speech-in-noise perception will be examined for the three groups of older adults and gains will be compared to a control group of young, normal hearing adults (18-30 years) that is not part of the clinical trial and will not undergo any training.",[233,234],"Speech Intelligibility","Aging",[236,234,237],"Auditory-cognitive training","Speech-in-noise perception","2025-04-03",{"date":240,"type":36},"2025-04-08",{"date":242,"type":36},"2021-09-27",{"date":150,"type":22},{"name":42,"class":43},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":107},"100547255","neurocognitive-mechanisms-of-sentence-production-impairment-in-aphasia-100547255","NCT06405594","Neurocognitive Mechanisms of Sentence Production Impairment in Aphasia","sentence","Inclusion Criteria:\n\n* At least 18 years of age\n* Persons with acquired aphasia are defined as those with a language impairment following left hemisphere brain injury (most likely a stroke).\n* Neurotypical adults need to be either young (ages 18-30 years) or older (\\> 60 years)\n* Native (or primary) speakers of English\n\nExclusion Criteria:\n\n* Prior neurological or psychiatric diagnoses or developmental disabilities before the onset of aphasia\n* do not speak English fluently",{"count":253,"type":22},350,[25],"The proposed research is relevant to public health because stroke is a leading cause of long-term disability among older adults and communication impairments resulting from stroke have a significant negative impact on quality of life. By seeking to better understand post-stroke aphasia, this project lays the groundwork for development of new interventions, and aligns with NIDCD's priority areas 1 (understanding normal function), 2 (understanding diseases), and 3 (improving diagnosis, treatment, and prevention).",[257,258,259],"Aphasia, Acquired","Stroke","Healthy Aging","2024-08-28",{"date":262,"type":36},"2024-09-03",{"date":264,"type":36},"2024-08-01",{"date":266,"type":22},"2029-06",{"name":42,"class":43},""]